Background: Metastatic urothelial cancer (UC) is a lethal disease. Until 2016, cytotoxic chemotherapy with substantial toxicity was the only therapeutic option. In the first-line metastatic setting, cisplatin-based combination chemotherapy remains the standard of care. For cisplatinineligible patients, carboplatin-based regimens that are less efficacious are often substituted. In platinum-refractory patients, taxanes and vinflunine are the most commonly used. Recently, treatment options have largely expanded with the development of the immune checkpoint inhibitors (ICIs). Here, we review the rationale, clinical trial data and recent advances in biomarker development in the field of immuno-oncology in this disease site. We will also explore future directions of the field with respect to sequencing and combination strategies.
INTRODUCTION
Urothelial cancers (UCs) represent the ninth most common cancer worldwide. It is estimated that over 430 000 new cases of UCs are diagnosed, and 165 000 deaths occur annually. 1 Worldwide, there is greater variability of incidence than mortality. The major risk factor for UC is smoking. UCs exhibit aggressive biology. Outcomes of metastatic UC remain poor and have unfortunately not seen significant improvement over the last 20 years. 2 Median survival ranges from 12 to 14 months, and median 5-year overall survival (OS) rates are merely 5%. 3, 4 
CHEMOTHERAPY IN ADVANCED UC
The current standard first-line regimen is cisplatin-based combina- and cisplatin (MVAC, or high dose MVAC), or gemcitabine plus cisplatin (GC) in cisplatin-eligible patients. Although response rates are high (45%-72%), durability can be short and toxicity is significant. Furthermore, up to 50% of patients with metastatic disease are not eligible to receive cisplatin-based chemotherapy, often due to comorbidities, poor performance status, elderly age, or impaired renal function 5, 6 (Table 1 ). For cisplatin-ineligible patients, alternative first-line therapies, such as carboplatin-based combination therapies are used but confer shorter OS. 7, 8 The use of gemcitabine and carboplatin (GemCarbo) and methotrexate, carboplatin, vinblastine (M-CAV) have been limited by their toxicity, with severe neutropenia occurring in > 50% of patients, and treatment discontinuation frequency of 21%. 3, [8] [9] [10] As a result, many patients are offered best supportive care alone. 11, 12 Table 2 summarizes treatment outcomes of standard chemotherapies in first-line metastatic UC.
TA B L E 1
Cisplatin-ineligibility criteria in metastatic bladder cancer proposed by Galsky et al., 2011 5 Any one of the following:
WHO or ECOG PS ≥2, or Karnofsky PS 60-70%
Creatinine clearance (calculated or measured) <60 mL/min CTCAE v4 grade ≥2 peripheral neuropathy CTCAE v4 grade ≥2 audiometric hearing loss NYHA Class III heart failure Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; CTCAE, Common Terminology Criteria for Adverse Events; NYHA, New York Heart Association.
Upon progression, until 2016, there were no approved second-line treatments except in Europe where vinflunine had approval. Some patients could be considered for platinum-based rechallenge if disease progression occurred beyond 12 months. 13 Taxanes 14, 15 and vinflunine [16] [17] [18] were the most commonly used second-line agents.
Their activities are suboptimal, with response rates ranging from 10% to 15%, and median OS benefit of only a few months. There is, therefore, an unmet need for effective and safe first-and second-line therapies in this disease, especially in cisplatin-ineligible patients.
TARGETING THE IMMUNE SYSTEM
Recent advances in immuno-oncology (IO) have revolutionized cancer care for many disease sites. Advantages of utilizing the adaptive immune system include specificity of antigen recognition and thus lessening toxicity, adaptability to tumor genetic and epigenetic evolution, as well as memory of cellular response resulting in prolonged durability of response, even after treatment discontinuation. Various approaches enhancing tumor recognition and cell killing by the immune system have been adopted in oncology, including immune checkpoint inhibitors (ICIs), such as inhibitory antibodies to programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen, vaccines, and more recently chimeric antigen receptor T-cells. 19 T-cell activation in peripheral lymph nodes requires antigen presentation on MHC I/II molecules to T-cell receptor (TCR) activation on antigen-presenting cells (APC), such as dendritic cells, costimulation (most commonly from B7-ligands on APCs binding to CD28 receptors on T-cells enabling CD40 pathway signaling) and instructive cytokine release by APCs (Figure 1 ). In addition, there may be another step of Tcell activation in the peripheral tissues that fully commit the activated T-cells to the effector phenotype, according to the two-step activation theory. 21 This then triggers downstream signaling cascade and subsequent T-cell activation.
To regulate uncontrolled T-cell activation, so called "immune checkpoints" exist. PD-L1 on tumor cells (TCs) sends a negative regulatory signal to tumor-infiltrating immune cells (ICs) via PD-1 to dampen the immune response 22 (Figure 2) . Therefore, the degree of immune activation depends on the extent of APC-mediated T-cell activation, costimulatory signals on APCs, and checkpoint receptor signaling. On the other hand, prolonged exposure to antigens can induce T-cell exhaustion, characterized by loss of effector cytotoxic functions and sustained expression of inhibitory molecules. 24, 25 This likely plays a significant role in the tumor microenvironment.
Checkpoint receptors play a significant role in the initial T-cell activation in lymph nodes, second activation in peripheral tissues and also in T-cell exhaustion. 26 Blockade of the PD-1/PD-L1 pathway has been the most successful class of immunotherapeutics to date. ICIs likely induce their anti-tumor effects through a multifaceted combination of promotion of T-cell activation by APCs and reversal of exhausted T-cells. [26] [27] [28] 
IMMUNOTHERAPY IN UCs
Although there have been rapid developments in IO in recent years across multiple disease sites, this field is not entirely new. Early observations established an important role for imunotherapeutics in UCs. As early as 1908, Bacillus Calmette-Guerin (BCG) vaccine was first used in humans, and in 1976, the first human study of intravesical BCG was used for nonmuscle invasive bladder cancer. BCG was later approved by the US Food and Drug Administration (FDA) in 1990. 29 UCs harbor high-somatic mutation rates compared to other cancers, and therefore, may have high immunogenicity and is potentially a suitable target for immunotherapy. 30 (20%-30%), suggesting tumor-associated tolerance and escape from immune surveillance. 32, 33 PD-L1 has shown to be prognostic in UC, with association of higher pathologic stage and all-cause mortality. 33, 34 These preliminary findings provide the rationale for piloting ICIs targeting the PD-1/PD-L1 pathway in metastatic UCs. Atezolizumab is an engineered, human monoclonal IgG1 antibody that targets and inhibits PD-L1 on TCs. 35 The IMvigor 210 phase II study enrolled 315 patients with metastatic UC (21% had upper tract primaries) who had disease progression on platinum-based chemotherapy or within 12 months of perioperative chemotherapy. 36 Patients received atezolizumab 1200 mg intravenously (IV) every 3 weeks until disease progression or unacceptable toxicity. Objective response rates (ORRs) were 15% compared with 10% in historical controls; 9.5% in patients with PD-L1 expression < 5% (two-thirds of all patients), and 26% in patients with PD-L1 expression ≥ 5% (one-third of all patients). PD-L1 status was determined by immunohistochem- with PD-L1 expression ≥ 1%, and 6 months in patients with PD-L1 < 1%. PD-L1 expression on both TCs and ICs were evaluated using the Ventana SP142 IHC assay. Severe adverse events occurred in 18% of patients, and three patients died from treatment-related complications (pneumonitis, acute respiratory failure, and cardiovascular failure). Nivolumab also led to at least stable, or in some cases improved health-related quality of life. 37, 38 Durvalumab is another human IgG1 monoclonal antibody targeting PD-L1, similar to atezolizumab. Its approval was based on a phase I/II study including 61 patients with advanced urothelial bladder cancer (no upper tract primaries) who progressed after platinum-based chemotherapy. 39 Unlike the other single-arm studies, durvalumab (10 mg/kg IV every 2 weeks) was only administered up to 12 months, and the primary endpoint was safety instead of ORR. Updated analysis of this trial has been published 40 Avelumab, similar to durvalumab and atezolizumab, is a human IgG1 monoclonal antibody targeting PD-L1. Unlike the other ICIs, avelumab also effects antibody-dependent cytotoxicity (ADCC) lysis of tumor cells. 41, 42 Avelumab was tested in the phase I JAVELIN study. 43 Two pooled cohorts (initial cohort n = 44 and efficacy expansion cohort n = 205) included a total 249 patients with advanced UC (23% with upper tract primaries) with disease progression after platinumbased chemotherapy. Seven patients who were cisplatin-ineligible and platinum-naive were also included; however, significant renal impairment (estimated glomerular filtration rate < 50 mL/min/1.73 m 2 ) was not allowed. Visceral disease was present in 84% of patients. Avelumab was administered as 10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity. This study only selected 161 patients with at least 6 months of follow-up for their efficacy analysis that can introduce significant bias. ORR was reported as 17%, including 6%
Immunotherapy in platinum-refractory disease
CR. Median time to response was 11.4 weeks, which is longer than reported in other ICI studies. After a median follow-up of 9.9 months, median duration of response was not reached. As only 27 responders had ≥ 6 months follow-up and were analyzed for subgroup analyses, these results should be interpreted with caution. This study also 
Immunotherapy in first-line cisplatin-ineligible patients
In previously untreated advanced UCs, FDA has approved the use of atezolizumab and pembrolizumab. The IMvigor210 phase II study was the first study published using ICI in this setting. In total 119 patients who were cisplatin-ineligible received atezolizumab (1200 mg IV every 3 weeks) until disease progression or unacceptable toxicity. 47 This cohort had a median age of 73, 81% were male, 66% had visceral metastases, 20% were ECOG 2, and 70% had baseline renal dysfunction (with a median creatinine clearance ≤ 50 mL/min). Upper tract primaries were also included (28%) in this study. Median OS was 15.9 months, and 57% of patients were alive at 1 year. Interestingly, median OS in patients with upper tract primary tumors had not been reached.
In the overall study population, ORR was 23%, of which 9% were CRs.
PD-L1 expression on tumor-infiltrating ICs were evaluated using Ventana SP142 IHC assay and cut-off points of < 1%, 1%-4%, and ≥ 5%.
Somatic mutation and TMB assessments were made using the commercially available FoundationOne DNA-based panel. Notably, consistent responses were seen across all PD-L1 expression subgroups (21% to 28%), however, higher TMB and TCGA luminal II subtype These data suggest immunotherapy has activity and acceptable toxicity profile in untreated cisplatin-ineligible advanced UCs. Phase 3 studies are under way. Although crosstrial comparisons are never definitive, treatment outcomes of atezolizumab and pembrolizumab in this setting seem to suggest at least similar activity to conventional cytotoxic chemotherapy, as demonstrated by the EORTC 30986 study. 8 In that trial, gemcitabine and carboplatin and M-CAV produced ORR of 36.1% and 21.0%, and median OS of 9.3 and 8.1 months,
respectively, but at a higher cost of toxicity than the ICI.
PATIENT SELECTION AND BIOMARKERS
ICIs in metastatic UCs have led to dramatic success in a minority of patients. All approved agents have similar ORR of 15%-23% in unselected patients in the second-line setting. However, there is a lack TA B L E 3 Updated summary of immunotherapy trials in metastatic urothelial cancer of predictive biomarkers to enable treatment stratification and better patient selection.
PD-L1 expression
PD-L1 has been the most well-characterized biomarker for immunotherapy. PD-L1 status is determined by the percentage of TCs or tumor-associated ICs with staining at any intensity above background. However, its utility as a predictive biomarker has been limited.
First, PD-L1 testing protocols are not uniform and vary substantially across studies (Table 3) . SP142 assay used in atezolizumab trials seems to have less sensitivity of PD-L1-positive ICs than other assays. 49, 50 As discussed previously, pembrolizumab and nivolumab studies used Recent longitudinal analysis of tumor tissues also illustrates adaptive regulation of PD-L1 expression following ICI therapy. 51 More importantly, the negative predictive value of PD-L1 is poor as responses are seen in patients with PD-L1-negative disease, and thus cannot be used to deny ICI in this subgroup of patients. Although PD-L1 has several advantages, including quick turn-around time and relatively inexpensive cost, existing data from large trials suggests that PD-L1 expression alone is unlikely to yield sufficient predictive capacity to guide patient selection for checkpoint inhibitors.
TCGA subtyping
TCGA UC subtypes have been shown to be prognostic for PD-1/PD-L1-directed therapy. 52 Certain tumor subtyping has also shown differentiation of response rates. TCGA luminal subtypes demonstrated higher ORR with atezolizumab, 36 while basal subtypes had higher ORR with nivolumab. 37 Whether these disparities are attributed to variability in protocols defining TCGA subtype or different targets of ICI are unknown. Although distinct TCGA classifications are proposed, standardization is lacking and only small numbers of tumor specimens were tested with multiple gene clusters. 52 It is also unknown whether deeper sequencing are required to appropriately identify the TCGA subtypes. 53, 54 Again, TCGA subtyping has low-negative predictive values given responses are seen in all clusters. Furthermore, the tumor immune microenvironment is not assessed with this approach. Taken together, TCGA subtype alone seems to have limited potential as an ideal predictive biomarker in metastatic UC.
Tumor mutational burden
TMB has emerged as a potential predictor of response to immunotherapy. High TMB has been associated with ORR of ICIs and longer duration of response. [55] [56] [57] However, TMB analysis is difficult to standardize. Uncertainties exist as to the impact of single nucleotide polymorphisms, depth of sequencing, and evolution of tumor over time. 58, 59 In addition, evolution of tumor over time may change the relative mutation burden. Snyder et al performed an indepth analysis of 29 metastatic UC patients treated with atezolizumab in the IMvigor 210 trial to determine whether (1) TMB and neoantigen load, and (2) intratumoral and peripheral blood TCR clonality correlated with therapeutic benefit. 60 Their analysis involved whole-exome sequencing, RNA sequencing, and TCR sequencing of pretreatment tumor specimens and serially collected peripheral blood. In this small dataset, diverse repertoire of peripheral T-cells pretreatment and higher tumor-infiltrating lymphocyte proportion at baseline were associated with durable clinical benefit. Patients with substantial expansion of tumor-associated peripheral TCR clones 3 weeks after starting treatment also had more favorable outcomes, interestingly, no significant association between mutation or expressed neoantigen load and PFS or durable response were found.
However, there seems to be a delayed relationship between mutation load and outcome in patients surviving greater than 3 months. Certain clinical variables, such as liver metastases are associated with poorer treatment outcomes. This further supports the idea that immunotherapy treatment outcomes are dependent on the interplay between tumor neoantigens, host immune repertoire, and response, as well as the patient's clinical status; and guide integrated multiomics biomarker development in future studies.
Immune cell gene expression profiling
Immune cell gene expression profiling (GEP) has several advantages, including high reproducibility relative to PD-L1 IHC, and the potential of directly assessing tumor immunogenicity through quantification of RNA expression profiles. GEP correlates with response to ICIs. 61 However, similar shortcomings exist, such as absence of a standardized panel and low negative predictive value. It also incurs significant cost that may limit its widespread application.
FUTURE DIRECTIONS

Sequencing therapies in advanced UC
Now that there is data supporting ICIs in both platinum-refractory and previously untreated cisplatin-ineligible setting, they are being evaluated in even earlier settings of the disease. The optimal timing for introducing ICI, however, remains unclear. This is particular relevant in a subset of patients who progress rapidly following immunotherapy. 47 Szabados et al. conducted a retrospective study to evaluate the response rates of chemotherapy following disease progression on IO, in patients with advanced UC. 62 Cohort A consisted of 14 patients who received first-line ICI upon diagnosis, and thereafter, received second-line chemotherapy. Cohort B included 14 patients who received front-line chemotherapy, second-line ICI, followed by third-line chemotherapy. Perhaps not surprisingly, response rates to chemotherapy after ICI were higher in cohort A than cohort B (64% vs. 21%), and in line with response rates previously demonstrated with second-line chemotherapy prior to IO availability. 63, 64 Despite limitations of a small-retrospective study population and lack of OS data, these results suggest that activity of chemotherapy is preserved following ICI therapy, and there is a lack of crossresistance between these two classes of therapy.
More studies are needed to see whether chemotherapy confers similar efficacy following ICI therapy. Whether or not the optimal approach is sequencing or a combination-based strategy will be addressed in upcoming trials.
Combination immunotherapy trials
Over the last few years, there have been a multitude of trials of PD-1/PD-L1 agents both as single agents and combination with chemotherapy. Two ongoing studies will hopefully decipher the optimal treatment approach in treatment-naïve advanced UC. The IMvigor 130 study (ClinicalTrials.gov NCT03807636) plans to enroll 1200 patients and randomize them to atezolizumab, atezolizumab plus chemotherapy (platinum and gemcitabine), or chemotherapy alone.
The KEYNOTE-361 (ClinicalTrials.gov NCT02853305) trial has the same treatment arms with pembrolizumab and plans to enroll 990 patients. Both studies are actively recruiting and final data for analysis are anticipated in January 2019. Other combination strategies including with radiotherapy are also planned. 65 Whether combination immunotherapy is superior to immunotherapy or chemotherapy alone in the first-line setting will be addressed by DANUBE and CheckMate 901. DANUBE (ClinicalTrials.gov NCT02516241) is a phase III trial that aims to randomize 1005 untreated patients to durvalumab, durvalumab plus tremelimumab, or chemotherapy (platinum/gemcitabine). CheckMate 901 (ClinicalTrials.gov NCT03036098) is another randomized phase III trial that plans on treating 897 patients with either nivolumab plus ipilumab, nivolumab plus cisplatin/gemcitabine, or platinum/gemcitabine plus placebo. Preliminary data from the phase I/II CheckMate 032 trial (n = 208) showed ORR of 38% and 26% at higher (3 mg/kg ipilimumab plus 1 mg/kg nivolumab) and lower doses of ipilimumab (1 mg/kg ipilimumab plus 3 mg/kg nivolumab). 66 Nivolumab plus ipilimumab also demonstrated small signals of activity in a small cohort of 40 patients with nivolumab-refractory disease. 67 Trials studying other novel combinations with immunomodulatory agents, including nivolumab plus cabozantinib or other tyrosine kinase inhibitors are also under way. 68 KEYNOTE-698 (ClinicalTrials.gov NCT03374488) is also testing the combination of pembrolizumab and epacadostat, an indoleamine 2,3 dioxygenase inhibitor. Maintenance therapy using ICI following response to first-line platinum chemotherapy are also being investigated.
CONCLUSIONS
The emergence of ICIs has dramatically altered the therapeutic landscape for metastatic UC in recent years, offering durable responses, more favorable toxicity, and improved quality of life relative to conventional chemotherapy. However, many patients with this disease do not benefit from immunotherapy, and uniform, reliable biomarkers are lacking. The optimal sequencing and combination strategy integrating immunotherapy in the current therapeutic landscape is yet to be elucidated.
